OKCEL

OKCEL is a clinical-stage biotechnology company based in Istanbul, Turkey, specializing in the development and manufacturing of advanced cell and gene therapies. Founded by the prominent scientist Prof. Dr. Ercüment Ovalı, the company focuses on chimeric antigen receptor T-cell (CAR-T) therapies for hematological malignancies and solid tumors. OKCEL operates a state-of-the-art GMP-certified facility located within the Acibadem University campus, which supports both its internal pipeline and contract manufacturing services. Their lead candidate, ISIK-19, is a CD19-targeted CAR-T therapy currently in Phase 1/2 clinical trials for B-cell leukemia and lymphoma. The company leverages its strategic partnership with the Acibadem Healthcare Group to accelerate the clinical translation and commercialization of its innovative immunotherapies.